COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    AdAlta
Previous Study | Return to List | Next Study

Phase 1 Safety, Tolerability, PK & PD Study of AD-214 Administered to Healthy Volunteers and Patients With ILD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04415671
Recruitment Status : Recruiting
First Posted : June 4, 2020
Last Update Posted : November 6, 2020
Sponsor:
Information provided by (Responsible Party):
AdAlta Limited

Brief Summary:
This is a first in human (FIH), multi-center, dose escalating study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and immunogenicity of AD-214 when administered to healthy volunteers (HVs) and to patients with Interstitial Lung Disease (ILD). The study in HVs will be single ascending dose (SAD), randomized, double blind, and placebo-controlled (Part A). The study in ILD patients will be open-label, SAD (Part B), and multiple ascending dose (MAD) (Part C).

Condition or disease Intervention/treatment Phase
Interstitial Lung Disease Biological: AD-214 Other: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 98 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: SAD Part A in HVs- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) SAD Part B in ILD patients- None (Open Label) SAD Part C in ILD patients - None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Dose-escalating Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of AD-214 When Administered Intravenously to Healthy Volunteers and to Patients With Interstitial Lung Disease
Actual Study Start Date : June 19, 2020
Estimated Primary Completion Date : July 31, 2022
Estimated Study Completion Date : July 31, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Part A- AD-214 SAD in Healthy Volunteers Biological: AD-214
AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Placebo Comparator: Part A-Placebo SAD in Healthy Volunteers Other: Placebo
Placebo

Experimental: Part B- AD-214 SAD in patients with ILD Biological: AD-214
AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.

Experimental: Part C-AD-214 MAD in patients with ILD Biological: AD-214
AD-214 is a recombinant Fc-fusion protein that selectively binds to CXCR4 to antagonise the SDF-1/CXCR4 axis.




Primary Outcome Measures :
  1. Safety and Tolerability as assessed by the number of abnormal laboratory values and/or adverse events that are related to treatment [ Time Frame: SAD Part A & B - 28 days. MAD Part C - 50 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

All Study Parts:

  1. Must provide signed informed consent prior to study entry and agree to adhere to all study protocol requirements.
  2. Maximum weight of 100 kg at the time of consent and body mass index (BMI) >18 and < 30 kg/m2 (inclusive)
  3. Must agree to abstain from alcohol intake from 48 hours before first study drug administration through to final study visit
  4. Must agree to abstain from smoking from 48 hours before first study drug administration through to final study visit
  5. Must have a negative urine drug screen and cotinine test, and alcohol breath test at Screening and on Day -1 (admission).
  6. Must agree to use highly effective, double barrier contraception (both male and female partners) at least 30 days prior to dosing on day 1, during the study AND for 90 days following completion of dosing
  7. Male participants must refrain from sperm donation from start of study and for 90 days after last dose of AD-214
  8. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at Screening and a negative urine pregnancy test on Day -1.

    Part A (SAD) in Healthy Volunteers:

  9. Participants must be in good general health, with no significant medical history, and no clinically significant abnormalities on physical examination at Screening, and/or before administration of the initial dose of study drug.
  10. Participants must have clinical laboratory values within normal range or < 1.5 x upper limit of normal (ULN) as specified by the testing laboratory at Screening.

    Part B (SAD) and Part C (MAD) (Interstitial Lung Disease):

  11. Patients with clinical and radiological features that in the opinion of the PI are consistent with a diagnosis of fibrotic ILD associated with idiopathic pulmonary fibrosis (IPF), Collagen-vascular disease (CVD), Fibrotic non-specific interstitial pneumonia (fNSIP) or Chronic fibrosing hypersensitivity pneumonitis (cHP).
  12. Predicted forced vital capacity (FVC) ≥ 50% on pulmonary function tests (PFTs) conducted within 3 months of Screening.
  13. Predicted haemoglobin-corrected diffusing capacity of the lung for carbon monoxide (DLCO) ≥ 25% in PFTs conducted within 6 months of Screening.

Exclusion Criteria:

All Study Parts:

  1. Received any Investigational Medicinal Product (IMP) within 30 days (4 months if the previous drug was a new chemical entity) or 5 half-lives prior to Screening
  2. Received an investigational vaccine within 6 months, a live attenuated vaccine within 60 days or a registered vaccine within 30 days prior to the first dose of the investigational product.
  3. Received blood products within 1 month prior to Screening.
  4. Blood donation or significant blood loss (> 450 mL) within 60 days prior to the first administration of investigational product
  5. Plasma donation within 7 days prior to the first administration of investigational product.
  6. A bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with blood draws.
  7. Known history of Human Immunodeficiency Virus (HIV) or HIV antibody positive.
  8. Hepatitis B surface Antigen (HBsAg) positive or Hepatitis B Virus (HBV) polymerase chain reaction (PCR) positivity. Hepatitis C Virus (HCV) antibody positive or HCV PCR positivity.
  9. Any clinically significant abnormality at Screening determined by medical history, physical examination, blood chemistry, hematology, coagulation, urinalysis and 12-lead electrocardiogram (ECG).
  10. A history of or current clinically significant gastrointestinal, hepatic, renal, cardiovascular, respiratory (apart from ILD), endocrine, oncological, immunodeficiency, neurological, metabolic, hematological, autoimmune or social or psychiatric condition which in the investigator's opinion may interfere with the study objectives, may put the participant at risk or may make the participant unsuitable for participation in the study.
  11. Surgery within the past 3 months prior to the first study drug administration determined by the PI to be clinically relevant.
  12. History or presence of alcohol or drug abuse
  13. Females who are pregnant or lactating.

    Part A (SAD) in Healthy Volunteers:

  14. Use of any prescription or over the counter medication (with the exception of paracetamol and contraceptives) within 7 days of first study drug administration.

    Part B (SAD) and Part C (MAD) in Patients with Interstitial Lung Disease:

  15. Received nintedanib or pirfenidone or other systemic medications for their ILD within 30 days of Day -1. Ongoing use of systemic corticosteroids (prednisolone or equivalent) at a dose of ≤ 10 mg/day is permitted.
  16. Evidence of significant deterioration in pulmonary function in the preceding 30 days at Screening and on Day -1.
  17. Significant hypoxia, requiring >2 L/min oxygen chronically to maintain a resting oxygen saturation >89% (at Screening).
  18. Poor exercise tolerance with 6 Minute Walking Distance (6MWD) < 150 m (at Screening).
  19. Extensive emphysema on HRCT as defined by being greater in extent than the accompanying fibrotic lung disease.
  20. Evidence of physiologically significant obstructive airways disease
  21. Other explanation for lung fibrosis, including but not limited to radiation, sarcoidosis, bronchiolitis obliterans organizing pneumonia.
  22. Alanine transferase (ALT) >2 x ULN OR total bilirubin >1.5 x ULN at screening.
  23. Use of anticoagulants or antiplatelet agents (excluding aspirin) at Screening and Day -1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04415671


Contacts
Layout table for location contacts
Contact: Claudia C Gregorio-King, PhD +61 3 9479 5159 clinical@adalta.com.au

Locations
Layout table for location information
Australia, New South Wales
Scientia Clinical Research Ltd Not yet recruiting
Randwick, New South Wales, Australia, 2031
Contact: Puja Motwani    +61 02 9382 5820    puja.motwani@scientiaclinicalresearch.com.au   
Principal Investigator: Charlotte Lemech, Dr         
Australia, South Australia
CMAX Clinical Research Pty Ltd Recruiting
Adelaide, South Australia, Australia, 5000
Contact: Dianne Pepper    +61 8 7088 7939    dianne.pepper@cmax.com.au   
Principal Investigator: Sepehr Shakib, Dr         
Sponsors and Collaborators
AdAlta Limited
Layout table for additonal information
Responsible Party: AdAlta Limited
ClinicalTrials.gov Identifier: NCT04415671    
Other Study ID Numbers: ADA-AD-214-1A
First Posted: June 4, 2020    Key Record Dates
Last Update Posted: November 6, 2020
Last Verified: July 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Interstitial
Respiratory Tract Diseases